Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 InhibitorBRISBANE, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Tenvie Therapeutics, a biotechnology company developing precision‑engineered small molecule therapies to transform the treatment of neurological and peripheral diseases, today announced the first subject dosed in a Phase 1 clinical study evaluating TNV262, a fully CNS-penetrant small molecule inhibitor targeting NLRP3 for the treatment of cardiometabolic diseases, including obesity and cardiovascular disease (CVD), as well as multiple sclerosis (MS). The Phase 1a/1b study will evaluate the safety and tolerability of single and multiple ascending doses of TNV262 as well as cardiovascular and inflammatory biomarkers in healthy volunteers and persons with obesity.
Tenvie Therapeutics Appoints Don O’Sullivan, Ph.D., MBA, as Chief Business OfficerSeasoned biotechnology executive with more than 20 years of corporate and business development experience to lead strategic collaborations and business operations
Tenvie Therapeutics Promotes Tony Estrada, PhD, to Chief Executive OfficerProven drug development leader to drive company’s pipeline of highly CNS-penetrant and precision-designed peripherally restricted small molecules toward clinical milestones
Tenvie Therapeutics Launches with $200 Million to Deliver Breakthrough Small Molecule TherapiesAdvancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases
